ProQR Therapeutics N.V. (PRQR) Raised to Hold at ValuEngine
ProQR Therapeutics N.V. (NASDAQ:PRQR) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Tuesday, August 22nd. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research report on Tuesday, June 20th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.30.
Shares of ProQR Therapeutics N.V. (PRQR) traded up 1.68% on Friday, reaching $6.05. 140,634 shares of the company’s stock were exchanged. The stock’s market cap is $145.84 million. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The company’s 50 day moving average is $5.11 and its 200-day moving average is $4.97.
Several large investors have recently added to or reduced their stakes in the company. Redmile Group LLC lifted its position in shares of ProQR Therapeutics N.V. by 2.8% during the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after purchasing an additional 43,050 shares during the last quarter. Artal Group S.A. lifted its position in shares of ProQR Therapeutics N.V. by 25.0% during the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after purchasing an additional 100,000 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of ProQR Therapeutics N.V. during the second quarter worth $2,028,000. Finally, Sphera Funds Management LTD. lifted its position in shares of ProQR Therapeutics N.V. by 65.0% during the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after purchasing an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 35.93% of the company’s stock.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.